NEWS & MEDIA · February 2, 2024
WIRED: Can a tiny biotech make insulin dirt-cheap?
This article summarizes coverage published on February 2, 2024.
About this coverage
WIRED examined rBIO’s work in the context of insulin affordability and the established insulin supply chain. The feature introduced R-biolin and explored the possibility of reducing manufacturing costs through a different production approach.
The article discusses the relationship between process innovation, scale-up and patient access. It presents the ambitions of an emerging biotechnology company alongside the development steps still needed to reach patients.
This is an archived news summary; development plans described here reflect the original publication date.